causal

Tech transfer is a bigger biotech bottleneck

The main barrier to commercializing research from institutions is not the technology itself but the opaque technology-transfer process, which is a structural inhibitor that must be solved to speed up innovation.

causalpending

Speaker

Daniel Ek

Evidence Quote

“there are also a lot of structural inhibitors, maybe more so than the technology in itself, that makes some of that not happening”

Source

Daniel Ek - Enabling Creators Everywhere - [Invest Like the Best, EP. 242]— Invest Like the Best
Created: 11/12/2026, 12:38:10 AM

Your notes

Loading notes...